943976-22-5

Upstream product

• 946530-08-1 C₂₆H₃₆N₄O₃ 
• 943962-57-0 methyl 4-((2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)(pyridin-2-yl)carbamoyl)cyclohexanecarboxylate 
• 146714-63-8 4-(2-methoxyphenyl)-1-(2-pyridinylaminocarbonyl)methylpiperazine 
• 504-29-0 2-aminopyridine 
• 5221-37-4 2-chloro-N-pyridin-2-ylacetamide 
• 946530-10-5 (1r,4r)-4-((2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)(pyridin-2-yl)carbamoyl)cyclohexylmethyl 4-methylbenzenesulfonate 
• 155204-28-7 1-(2-methoxyphenyl)-4-(2-(2-pyridylamino)ethyl)piperazine 
• 13170-66-6 trans-1,4-cyclohexanedicarboxylic acid dichloride 
• 619-82-9 trans-hexahydroterephthalic acid 
• 1421268-46-3 (1r,4r)-4-((2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)(pyridin-2-yl)carbamoyl)cyclohexanecarboxylic acid 
• 946530-07-0 (1r,4r)-4-(hydroxymethyl)-N-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-N-(pyridin-2-yl)cyclohexanecarboxamide 
• 407628-30-2 trans-1,4-cyclohexane dicarboxylic acid 
• 943962-58-1 4-(hydroxymethyl)-N-(2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl)-N-(pyridin-2-yl)cyclohexanecarboxamide 

Relevant academic research and scientific papers

Synthesis and evaluation of mefway analogs as ligands for serotonin 5HT1A receptors

18F-Mefway (N-{2-[4-(2′methoxyphenyl)piperazinyl]ethyl}-N-(2-pyridyl)-N-(4′18F-fluoro-methylcyclohexane)carboxamide) was developed and evaluated for use as a PET ligand for imaging 5-HT1A receptors. Ongoing studies of sup

5HT1A ANTAGONIST USEFUL FOR IN VIVO IMAGING

The present invention provides a novel compound of formula (I) useful for in vivo imaging of 5-HT1 A receptors in a subject. Also provided by the present invention is a precursor compound useful in the preparation of the compound of the inventi

NOVEL SYNTHESIS METHOD

The present invention relates to a method of making compounds having affinity for the 1 A subtype of the serotonin receptor, i.e. 5HT1A. The method of the present invention provides advantages over the known methods of synthesis. The compounds

COMPOSITIONS AND METHODS RELATED TO SEROTONIN 5-HT1A RECEPTORS

Contemplated substituted arylpiperazinyl compounds, and most preferably 18F-Mefway, exhibit desirable in vitro and in vivo binding characteristics to the 5-HT1A receptor. Among other advantageous parameters, contemplated compounds retain high b